Compile Data Set for Download or QSAR
maximum 50k data
Found 820 of ki data for polymerid = 2174,6595
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US10123984, Example 2A | US10744104, Example 2A | ...)
Affinity DataKi:  0.200nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411736(CHEMBL271225)
Affinity DataKi:  0.280nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582847(US11547687, Comparative Compound I | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.501nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617465(US20230285340, Example 5A)
Affinity DataKi:  0.631nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50024101((S)-2-((S)-2-Mercaptomethyl-3-phenyl-propionylamin...)
Affinity DataKi:  0.700nMAssay Description:Inhibition of human recombinant NEP using Suc-Ala-Ala-Phe-AMC as substrate after 30 mins by fluorimetryMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Oryctolagus cuniculus (rabbit))
University Of Paris

Curated by ChEMBL
LigandPNGBDBM21653((2S)-2-[(2R)-2-[(1R)-2,3-dihydro-1H-inden-1-yl]-3-...)
Affinity DataKi:  0.700nMAssay Description:In vitro inhibition of Neutral endopeptidase.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Oryctolagus cuniculus (rabbit))
University Of Paris

Curated by ChEMBL
LigandPNGBDBM21653((2S)-2-[(2R)-2-[(1R)-2,3-dihydro-1H-inden-1-yl]-3-...)
Affinity DataKi:  0.700nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:NEP was preincubated in black 96-well microplates with or without increasing concentrations of inhibitors. DGPA was added, and the reaction was stopp...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]-HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411731(CHEMBL257726)
Affinity DataKi:  0.800nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Oryctolagus cuniculus (rabbit))
University Of Paris

Curated by ChEMBL
LigandPNGBDBM50087104(C-{[3-Biphenyl-4-yl-2-(carboxymethyl-carbamoyl)-pr...)
Affinity DataKi:  0.940nMAssay Description:Inhibitory activity on neutral endopeptidase (NEP) using DGNPA as substrate.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US10123984, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US10123984, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(BDBM582703 | US10123984, Example 3A | US10123984, ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458399(US10744104, Example 3D | US20230285340, Example 3D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458388(US10744104, Example 1 | US10744104, Example 5-1 | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458402(US10744104, Example 5-5 | US20230285340, Example 5...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458403(US10744104, Example 5-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458404(US10744104, Example 5-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458405(US10744104, Example 5-14 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458406((2R,4R)-5-(3-Chlorobiphenyl-4-yl)-2-hydroxy-4-(oxa...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458407(US10744104, Example 5-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US10123984, Example 6A | US10744104, Example 6A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298307(US10123984, Example 8-2 | US10744104, Example 8-2 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298308(US10123984, Example 8-3 | US10744104, Example 8-3 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458416(US10744104, Example 11-2 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582844(US11547687, Comparative Compound G | US20230285340...)
Affinity DataKi:  1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459368(US10759813, Example 16-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459374(US10759813, Example 17-A)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459375(US10759813, Example 18-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459376(US10759813, Example 18-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459377(US10759813, Example 18-7)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459378(US10759813, Example 18-8)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459379(US10759813, Example 18-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459380(US10759813, Example 18-10)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459381(US10759813, Example 18-11)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459382(US10759813, Example 18-12)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459383(US10759813, Example 18-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459384(US10759813, Example 18-14)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459385(US10759813, Example 18-15)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459386(US10759813, Example 18-16)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459387(US10759813, Example 18-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459388(US10759813, Example 18-19)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459389(US10759813, Example 18-23)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459390(US10759813, Example 18-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459391(US10759813, Example 18-31)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 820 total ) | Next | Last >>
Jump to: